Castle Biosciences (CSTL) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Castle Biosciences (NASDAQ: CSTL) in the last few weeks:

• 8/3/2026 – Castle Biosciences had its price target raised by BTIG Research from $40.00 to $44.00. They now have a “buy” rating on the stock.
• 8/1/2026 – Castle Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/31/2026 – Castle Biosciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/31/2026 – Castle Biosciences was given a new $36.00 price target by Robert W. Baird.
• 6/24/2026 – Castle Biosciences is now covered by Roth Capital. They set a “buy” rating and a $40.00 price target on the stock.
• 6/24/2026 – Castle Biosciences was upgraded by Roth Capital to “strong-buy”.

Insider Transactions at Castle Biosciences

In related news, COO Kristen M. Oelschlager sold 8,586 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.77, for a total transaction of $255,605.22. Following the sale, the chief operating officer directly owned 13,288 shares of the company’s stock, valued at approximately $395,583.76. This represents a 39.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 2,546 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $30.68, for a total transaction of $78,111.28. Following the sale, the insider owned 21,479 shares of the company’s stock, valued at approximately $658,975.72. This represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 140,477 shares of company stock valued at $3,925,791. Insiders own 6.10% of the company’s stock.

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.